Tyson & Blake grows healthcare portfolio with StrongRoom AI
Global investment firm Tyson & Blake has announced its lead investment in Strong Room Technology, a medical innovation company aimed at improving pharmacy, methadone dispensing, and diagnosing to improve patient outcomes.
In response to the growth in Adverse Drug Events (ADE), resulting from medical interventions via drug treatments (medication errors, adverse drug reactions, allergic reactions, and overdoses), StrongRoom AI has created the next generation of drug management solutions. The technology leverages the power of facial recognition to advance medical care, using 3D Facial Mapping Techniques to capture facial biomarkers and expressions, correlating them to symptoms and diseases.
StrongRoom AI aggregates drug data across pharmacies, hospitals, and care homes providing unique patient and organisational insights. The business has grown rapidly over the last 12 months and is forecasting to win market share over the next two to three years driving real efficiencies and creating preventative healthcare solutions in these markets.
Simon Alexander Legge, managing director of Tyson & Blake commented: “Up to 1.5 million people die unnecessarily from adverse drug reactions every year. Now more than ever it is increasingly clear how digital processes are essential to delivering better outcomes. Partnered with the QS System from Quality Pharma, Strong Room’s drug management platform will help reduce the cost and risk of adverse drug reactions at scale, empowering individuals with critical information to actively engage in their own wellbeing and improving the quality and safety of professional healthcare. The focus on using AI to help eliminate adverse drug events is a hugely exciting development in the evolution of healthcare to SelfCare.”
Max Mito, co-founder and CEO of StrongRoom AI, said: “We are very excited to be working with Tyson & Blake to grow the business internationally. Their skilled executive team and wide adviser base provides a unique advantage in breaking into the UK, European and North American market. As of this moment, we are actively pursuing several international opportunities and with their expertise and raised funds...Ultimately, we are looking to eliminate adverse drug events (a $1T problem worldwide) and look to build the world’s best drug management platform."